Search This Blog

Friday, October 4, 2013

Single-Agent Ramucirumab Significantly Improves Overall Survival In Advanced Gastric Cancer Patients (NYSE:LLY)

Single-Agent Ramucirumab Significantly Improves Overall Survival In Advanced Gastric Cancer Patients (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.